Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes
In patients with type 2 diabetes who were also on insulin, tirzepatide led to significantly lower insulin requirements after 3, 6, and 12 months of use compared with dulaglutide and semaglutide. Tirzepatide also led to significantly more weight loss compared with dulaglutide and semaglutide and yielded a larger decrease in A1C overall without increasing side effects.
Authors
- Kristina Naseman (ORCID: https://orcid.org/0000-0003-4738-3785)
- Aric D. Schadler (ORCID: https://orcid.org/0000-0001-8814-5834)
- A. Leonhard
- Hayley M. Hall
- Delaney B. McKone
- Karolyn S. Duprey
Institutions
- University of Kentucky HealthCare (US)
- University of Kentucky (US)
Publication Details
- Journal
- Diabetes Spectrum
- Published
- 2025-02-20
- DOI
- https://doi.org/10.2337/ds24-0035
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Center for Clinical and Translational Science, University of Kentucky